Entropy Neurodynamics Limited (ENP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) has a cash flow conversion efficiency ratio of -0.110x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-809.59K ≈ $-572.83K USD) by net assets (AU$7.36 Million ≈ $5.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Entropy Neurodynamics Limited market capitalisation for the company's overall valuation and market capitalisation.
Entropy Neurodynamics Limited - Cash Flow Conversion Efficiency Trend (2018–2026)
This chart illustrates how Entropy Neurodynamics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Entropy Neurodynamics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entropy Neurodynamics Limited ranked by their cash flow conversion efficiency. See Entropy Neurodynamics Limited cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Digihost Technology Inc
V:DGHI
|
-0.819x |
|
Indonesia Energy
NYSE MKT:INDO
|
-0.054x |
|
Hyundai Industrial Co. Ltd
KQ:170030
|
-0.005x |
|
Cherrybro co.Ltd
KQ:066360
|
0.064x |
|
Viewbix Inc. Common Stock
NASDAQ:VBIX
|
-0.183x |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
-0.037x |
|
Elton International Trading Company S.A
AT:ELTON
|
0.056x |
|
Analabs Resources Bhd
KLSE:7083
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Entropy Neurodynamics Limited (2018–2026)
The table below shows the annual cash flow conversion efficiency of Entropy Neurodynamics Limited from 2018 to 2026. View ENP share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | AU$7.36 Million ≈ $5.21 Million |
AU$-3.41 Million ≈ $-2.41 Million |
-0.462x | +64.51% |
| 2025-06-30 | AU$5.96 Million ≈ $4.22 Million |
AU$-7.77 Million ≈ $-5.50 Million |
-1.303x | -22.03% |
| 2024-06-30 | AU$5.62 Million ≈ $3.98 Million |
AU$-6.00 Million ≈ $-4.25 Million |
-1.068x | -9.44% |
| 2023-06-30 | AU$4.13 Million ≈ $2.92 Million |
AU$-4.03 Million ≈ $-2.85 Million |
-0.975x | +0.01% |
| 2022-06-30 | AU$8.81 Million ≈ $6.23 Million |
AU$-8.59 Million ≈ $-6.08 Million |
-0.976x | -133.39% |
| 2021-06-30 | AU$18.87 Million ≈ $13.35 Million |
AU$-7.89 Million ≈ $-5.58 Million |
-0.418x | +68.78% |
| 2020-06-30 | AU$5.02 Million ≈ $3.55 Million |
AU$-6.72 Million ≈ $-4.75 Million |
-1.339x | -213.81% |
| 2019-06-30 | AU$5.12 Million ≈ $3.62 Million |
AU$-2.18 Million ≈ $-1.55 Million |
-0.427x | -103.30% |
| 2018-06-30 | AU$-7.27K ≈ $-5.14K |
AU$-93.93K ≈ $-66.46K |
12.924x | -- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more